🇺🇸 FDA
Pipeline program

Exon 51 specific phosphorothioate oligonucleotide

351-202

Phase 2 small_molecule active

Quick answer

Exon 51 specific phosphorothioate oligonucleotide for Duchenne Muscular Dystrophy is a Phase 2 program (small_molecule) at BioMarin International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
BioMarin International Limited
Indication
Duchenne Muscular Dystrophy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials